SCHEMBL17828729

SCHEMBL17828729

COc1cccc(-c2ccc(-c3nc(-n4c5ccccc5c5cc(-c6ccc7c(c6)c6ccccc6n7-c6ccccc6)ccc54)c4ccc5ccccc5c4n3)cc2)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABCG2 Q9UNQ0 4/20 0.45
CYP1A2 P05177 5/20 0.40
CYP3A4 P08684 5/20 0.40
CYP2D6 P10635 4/20 0.40
USP2 O75604 2/20 0.40
TSHR P16473 2/20 0.40
MAPK1 P28482 2/20 0.40
CLK4 Q9HAZ1 2/20 0.40
TSPO P30536 3/20 0.40
CYP2C9 P11712 3/20 0.39
TP53 P04637 2/20 0.39
ALOX15 P16050 1/20 0.39
CYP2C19 P33261 1/20 0.39
HSD17B10 Q99714 1/20 0.39
CYP2B6 P20813 2/20 0.39
AHR P35869 2/20 0.39
NR1I3 Q14994 2/20 0.39
VDR P11473 1/20 0.39
SIRT1 Q96EB6 1/20 0.38
XDH P47989 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17828750 0.98 ABCG2 (0.43) ABCG2CYP1A2CYP3A4CYP2D6USP2
SCHEMBL17828728 0.98 ABCG2 (0.46) ABCG2CYP1A2CYP3A4CYP2D6USP2
SCHEMBL17828760 0.94 ABCG2 (0.42) ABCG2CYP1A2CYP3A4CYP2D6USP2
SCHEMBL17828768 0.92 ABCG2 (0.42) ABCG2CYP1A2CYP3A4CYP2D6USP2
SCHEMBL17828730 0.90 ABCG2 (0.43) ABCG2CYP1A2CYP3A4CYP2D6USP2
SCHEMBL17829155 0.90 KDM4E (0.38) ABCG2CYP1A2TSPOATM
SCHEMBL17829136 0.89 L3MBTL1 (0.41) ABCG2CYP1A2TSPOMAPTATM
SCHEMBL17828870 0.89 KDM4E (0.41) ABCG2CYP1A2TSPOKMT2AATM
SCHEMBL17828873 0.89 KDM4E (0.38) ABCG2CYP1A2TSPOMAPTATM
SCHEMBL17829122 0.88 L3MBTL1 (0.42) ABCG2CYP1A2MAPTATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9508939-B2 Compound and organic electroluminescent element produced using same IDEMITSU KOSAN CO., LTD. (JP) 2016-11-29 US disclosed
US-9508939-B2 Compound and organic electroluminescent element produced using same IDEMITSU KOSAN CO., LTD. (JP) 2016-11-29 US disclosed
US-20160172604-A1 NOVEL COMPOUND AND ORGANIC ELECTROLUMINESCENT ELEMENT PRODUCED USING SAME IDEMITSU KOSAN CO., LTD. (JP) 2016-06-16 US disclosed
US-20160172604-A1 NOVEL COMPOUND AND ORGANIC ELECTROLUMINESCENT ELEMENT PRODUCED USING SAME IDEMITSU KOSAN CO., LTD. (JP) 2016-06-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160172604-A1 NOVEL COMPOUND AND ORGANIC ELECTROLUMINESCENT ELEMENT PRODUCED USING SAME L1CAM, LEF1, EML4 ABCG2 4502/4885CYP1A2 1870/4885CYP3A4 2550/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.